07:00 , Sep 25, 2014 |  BC Innovations  |  Cover Story

Interrupting Ebola

The 2014 Ebola outbreak is the largest in the disease's history and the first in West Africa, where it has reached multiple countries. Although an approved therapy looks far away, five of seven patients given...
07:00 , Jul 24, 2014 |  BC Innovations  |  Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
08:00 , Feb 17, 2014 |  BC Week In Review  |  Clinical News

AVI-7288: Phase I data

A double-blind, placebo-controlled, U.S. Phase I trial in 40 healthy volunteers showed that once-daily 1, 4, 8, 12 and 16 mg/kg doses of IV AVI-7288 for 14 days were well tolerated with no serious or...
07:00 , May 13, 2013 |  BC Week In Review  |  Clinical News

AVI-7288: Phase I started

Sarepta began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate multiple ascending-doses of 1, 3, 6 and 9 mg/kg IV AVI-7288 once daily for 14 days in 32 healthy volunteers. Sarepta is developing the...
07:00 , Mar 11, 2013 |  BC Week In Review  |  Clinical News

Sarepta Therapeutics preclinical data

In non-human primates infected with Marburg virus, once-daily 7.5-30 mg/kg doses of intramuscular AVI-7288 given 1 hour post-infection and for 13 subsequent days produced 83-100% survival rates over a 40-day evaluation period vs. 0% for...
07:00 , Oct 8, 2012 |  BC Week In Review  |  Company News

Sarepta Therapeutics, Tekmira, U.S. Department of Defense infectious, drug delivery news

The DoD will continue funding only Tekmira's Ebola medical countermeasure R&D contract after its and Sarepta's contracts were suspended in August due to government budget constraints. The government selected the TKM-Ebola program from Tekmira, which...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

AVI-7288 regulatory update

FDA granted Fast Track designation for Sarepta's AVI-7288 to treat Marburg virus infection and AVI-7537 to treat Ebola virus infection. Sarepta is developing the compounds, which are single oligomer nucleic acid analog based on morpholino-modified...
07:00 , Sep 24, 2012 |  BC Week In Review  |  Clinical News

AVI-7537 regulatory update

FDA granted Fast Track designation for Sarepta's AVI-7288 to treat Marburg virus infection and AVI-7537 to treat Ebola virus infection. Sarepta is developing the compounds, which are single oligomer nucleic acid analog based on morpholino-modified...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Company News

Sarepta Therapeutics, Tekmira, U.S. Department of Defense infectious, drug delivery news

The companies said the DoD extended an August stop-work order for their respective Ebola programs. The companies expect to receive notification from DoD by Sept. 30 on whether it will cancel the stop-work order, terminate...
07:00 , Sep 10, 2012 |  BC Week In Review  |  Company News

Sarepta Therapeutics, U.S. Department of Defense infectious news

Sarepta received a $3.9 million contract from DoD's Joint Project Manager Transformational Medical Technologies (JPM-TMT) program to evaluate the feasibility of intramuscular formulation of AVI-7288 to treat Marburg virus. Sarepta will evaluate safety, pharmacokinetics and...